Loading financial data...

Cardio Diagnostics Holdings, Inc. (CDIO) Financial Statements | Global Financial Data

Cardio Diagnostics Holdings, Inc.

CDIOSEC EDGAR

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 1870144

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$34.9K	$17.1K	$950.00	$901.00	—
Research and Development Expense	$228.0K	$145.2K	$40.4K	$31.5K	—
Operating Expenses	$8.4M	$7.3M	$4.5M	$621.3K	—
Operating Income (Loss)	-$8.4M	-$7.2M	-$4.5M	-$620.4K	-$145.3K
Interest Expense	$18.6K	$6.7M	$6.7M	—	—
Other Nonoperating Income (Expense)	-$17.6K	-$1.1M	-$112.5K	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$8.4M	-$8.4M	-$4.7M	-$620.4K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$10.6M	$4.5M	$6.2M	$1.1M	$65.8M
Assets, Current	$8.8M	$2.8M	$5.9M	$803.5K	$806.7K
Cash and Cash Equivalents, at Carrying Value	$0.00	$0.00	$0.00	$0.00	$0.00
Accounts Receivable, after Allowance for Credit Loss, Current	$18.6K	$5.0K	$5.0K	$901.00	—
Liabilities	$1.1M	$1.5M	$1.9M	$33.9K	$124.4K
Liabilities, Current	$631.7K	$841.1K	$1.9M	—	$124.4K
Stockholders' Equity Attributable to Parent	$3.0M	$4.3M	$1.1M	$60.4K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$5.0M	-$5.7M	-$5.1M	-$585.3K	-$300.9K
Net Cash Provided by (Used in) Investing Activities	-$404.2K	-$794.3K	-$368.0K	-$364.0K	-$65.0M
Net Cash Provided by (Used in) Financing Activities	$11.9M	$3.6M	$9.1M	$1.2M	$65.8M
Payments to Acquire Property, Plant, and Equipment	$214.8K	$575.7K	$575.7K	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)